Welcome to our dedicated page for Dynatrace SEC filings (Ticker: DT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to pin down Dynatrace’s subscription revenue mix or locate its ARR disclosures buried deep in a 10-K can feel like debugging production code at 2 a.m. The company’s SaaS model, stock-based compensation, and capitalized software costs turn every filing into a maze of tables and footnotes.
Stock Titan solves that problem. Our AI reads every Dynatrace annual report 10-K simplified, Dynatrace quarterly earnings report 10-Q filing, and Dynatrace 8-K material events explained the moment they hit EDGAR. Interactive summaries highlight ARR trends, cloud hosting margins, and goodwill amortization, while plain-English callouts answer the searches you actually run—“Dynatrace insider trading Form 4 transactions” or “Dynatrace proxy statement executive compensation.”
Need granular detail? Toggle straight to Dynatrace Form 4 insider transactions real-time to watch executives exercise options, compare segments across periods with one-click charts, or export data for your models. Whether you’re tracking Dynatrace earnings report filing analysis before a call, monitoring Dynatrace executive stock transactions Form 4, or simply understanding Dynatrace SEC documents with AI, every filing type—from S-8 registrations to 13G ownership updates—arrives instantly, already decoded. Spend less time scrolling PDFs and more time acting on insight.
Upstart Holdings, Inc. (UPST) – Form 144 insider notice
Insider Natalia Mirgorodskaya has filed to sell up to 6,533 common shares through Charles Schwab on or about 07/02/2025. At the reference price used in the filing, the transaction is valued at roughly $457,674. The shares were obtained the same day via an employee stock-option cashless exercise. Mirgorodskaya also disclosed two prior sales in the last three months—764 shares for $35,874 on 05/20/2025 and 1,340 shares for $59,215 on 05/23/2025.
With 95,144,858 shares outstanding, the proposed sale represents approximately 0.007 % of total shares, indicating a limited potential impact on the float. The filer certified that no undisclosed adverse information is known, in accordance with Rule 144 requirements.
Venus Concept Inc. (NASDAQ: VERO) has completed a series of related financing amendments designed to ease near-term liquidity pressure and realign its capital structure.
On 30 June 2025 the Company executed an Exchange Agreement with its senior lender Madryn Health Partners. Two existing secured subordinated convertible notes with aggregate principal of $17.0 million were exchanged for (i) new promissory notes totalling $11.1 million and (ii) 325,651 shares of newly issued Series Y Convertible Preferred Stock priced at $19.96 per share. Each preferred share converts into 9.0909 common shares, implying potential issuance of roughly 3.0 million additional common shares once conversion limits are lifted.
The transaction immediately reduces debt principal by about $5.9 million, shifts a portion of lender exposure into equity and carries no registration requirement under Section 3(a)(9). A Third Amended & Restated Registration Rights Agreement obligates the Company to file a shelf registration for the conversion shares within 60 days after all preferred shares convert.
Concurrently, the Company and Madryn executed several consent and amendment agreements: (1) waiver of minimum liquidity covenants on both the Main Street Priority Loan and the new notes through 31 July 2025, (2) permission to apply the 8 July 2025 interest payment to principal, and (3) a sixteenth amendment to the Bridge Loan extending maturity by one month to 31 July 2025.
To support the larger preferred issuance, Venus filed a Certificate of Amendment increasing authorized Series Y shares from 1.2 million to 1.5 million. A shareholder vote will be sought to remove Nasdaq-related conversion limits.
Overall, the package provides short-term covenant relief and modest debt reduction but adds potential equity dilution and highlights ongoing liquidity constraints, with several key maturities now deferred only to late July 2025.
FAQ
What is the current stock price of Dynatrace (DT)?
What is the market cap of Dynatrace (DT)?
What is the core business of Dynatrace Inc?
How does Dynatrace generate revenue?
What makes Dynatrace's platform unique?
Who are the primary users of Dynatrace's services?
What are the key features of Dynatrace's platform?
How does Dynatrace enhance IT operational efficiency?
How does Dynatrace differentiate itself from competitors?
What role do strategic partnerships play in Dynatrace’s business?
